Shoichi Hosoya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shoichi Hosoya has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Akira Yoshimoto
Department of Clinical Bioanalysis and Molecular Biology, Graduate School of Medical and Dental Sciences Institute of Science Tokyo/Tokyo Medical and Dental University (TMDU) Tokyo Japan
1 shared publication - Hiroaki Itoh
Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan
1 shared publication - Junhao Fu
The University of Tokyo
1 shared publication - Kai Kitamura
The University of Tokyo
1 shared publication - Kaori Sakurai
Department of Biotechnology and Life Science, Tokyo University of Agriculture and Technology, 2-24-16 Naka-cho, Koganei-shi, Tokyo 184-8588, Japan
1 shared publication - Koichi Kamiya
The University of Tokyo
1 shared publication
Latest Publications
- Open Access
- 21 January 2026
- Published by Portland Press Ltd. in Bioscience Reports
- Vol. 46 (1)
Homocysteine thiolactone affects paraoxonase 1 activity via altered paraoxonase 1 distribution on high-density lipoprotein particles
Hyperhomocysteinemia is a risk factor of cardiovascular disease (CVD). High-density lipoprotein (HDL) plays an important role in anti-atherosclerosis, with its anti-atherogenic function attributed to HDL-associated proteins such as apolipoprotein A-I (apoA-I) and paraoxonase 1 (PON1). Homocysteine (Hcy) thiolactone modifies lysine residues in proteins, thereby altering their function. Although dysfunction of apoA-I and PON1 has been reported, the precise modification sites and underlying mechanisms have remained unclear. In this study, we aimed to identify Hcy-thiolactone modification sites on apoA-I and PON1. In addition, we sought to clarify the effects of Hcy-thiolactone on PON1 activity and its distribution. Modification sites were analyzed using MALDI-TOF MS. The effects of Hcy-thiolactone on various specimens, including purified proteins, reconstituted HDL (rHDL), HDL collected by ultracentrifugation, and serum samples, were characterized using enzymatic assays measuring three major PON1 activities (arylesterase, paraoxonase, and lactonase) and Western blotting. Our results demonstrated that while some Hcy-thiolactone modification sites were detected on apoA-I, PON1 itself was not directly modified by Hcy-thiolactone. Thiolactonase activity was reduced by Hcy-thiolactone in large HDL particles. Furthermore, a general reduction of PON1 activity and changes in HDL remodeling and distribution were observed in serum samples treated with Hcy-thiolactone. These findings suggest that PON1 dysfunction induced by Hcy-thiolactone is influenced by alterations in HDL remodeling and the enzyme’s distribution on HDL particles. Analysis of PON1’s distribution dynamics under pathological conditions may provide crucial insights into the mechanism of HDL function decline in CVD.
- 21 January 2026
- Published by Portland Press Ltd. in Bioscience Reports
- Vol. 46 (1)
Open AccessHomocysteine thiolactone affects paraoxonase 1 activity via altered paraoxonase 1 distribution on high-density lipoprotein particles
Hyperhomocysteinemia is a risk factor of cardiovascular disease (CVD). High-density lipoprotein (HDL) plays an important role in anti-atherosclerosis, with its anti-atherogenic function attributed to HDL-associated proteins such as apolipoprotein A-I (apoA-I) and paraoxonase 1 (PON1). Homocysteine (Hcy) thiolactone modifies lysine residues in proteins, thereby altering their function. Although dysfunction of apoA-I and PON1 has been reported, the precise modification sites and underlying mechanisms have remained unclear. In this study, we aimed to identify Hcy-thiolactone modification sites on apoA-I and PON1. In addition, we sought to clarify the effects of Hcy-thiolactone on PON1 activity and its distribution. Modification sites were analyzed using MALDI-TOF MS. The effects of Hcy-thiolactone on various specimens, including purified proteins, reconstituted HDL (rHDL), HDL collected by ultracentrifugation, and serum samples, were characterized using enzymatic assays measuring three major PON1 activities (arylesterase, paraoxonase, and lactonase) and Western blotting. Our results demonstrated that while some Hcy-thiolactone modification sites were detected on apoA-I, PON1 itself was not directly modified by Hcy-thiolactone. Thiolactonase activity was reduced by Hcy-thiolactone in large HDL particles. Furthermore, a general reduction of PON1 activity and changes in HDL remodeling and distribution were observed in serum samples treated with Hcy-thiolactone. These findings suggest that PON1 dysfunction induced by Hcy-thiolactone is influenced by alterations in HDL remodeling and the enzyme’s distribution on HDL particles. Analysis of PON1’s distribution dynamics under pathological conditions may provide crucial insights into the mechanism of HDL function decline in CVD.
- Open Access
- 14 July 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Photoaffinity Labeling Strategy Reveals Tetraspanin CD9 as a Transient Target of Anticancer Yaku'amide B
Innovative chemical strategies are needed to understand the molecular targets of natural products, especially when they engage with multiple targets via transient interactions. Yaku’amide B (1), an anticancer natural product, inhibits mitochondrial FoF1-ATP synthase with nanomolar affinity; however, this mechanism alone does not explain its unique activity. Here, we employed photoaffinity labeling (PAL), a powerful, key strategy, and discovered that tetraspanin CD9 is a transient cell surface target of 1 in cancer cells. Comprehensive analyses revealed that 1 binds to the cyto-plasmic N-terminal region of CD9 with micromolar affinity, thereby accelerating its cellular entry, inducing CD9 de-pletion via lysosomal proteolysis and inhibiting cancer cell migration. Thus, 1 represents the first natural product that binds to and promotes the degradation of CD9. This study underscores the versatility of applying the PAL strategy for mechanistic studies and establishes 1 as a novel molecular platform for targeting CD9-mediated cellular pathways.
- 14 July 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessPhotoaffinity Labeling Strategy Reveals Tetraspanin CD9 as a Transient Target of Anticancer Yaku'amide B
Innovative chemical strategies are needed to understand the molecular targets of natural products, especially when they engage with multiple targets via transient interactions. Yaku’amide B (1), an anticancer natural product, inhibits mitochondrial FoF1-ATP synthase with nanomolar affinity; however, this mechanism alone does not explain its unique activity. Here, we employed photoaffinity labeling (PAL), a powerful, key strategy, and discovered that tetraspanin CD9 is a transient cell surface target of 1 in cancer cells. Comprehensive analyses revealed that 1 binds to the cyto-plasmic N-terminal region of CD9 with micromolar affinity, thereby accelerating its cellular entry, inducing CD9 de-pletion via lysosomal proteolysis and inhibiting cancer cell migration. Thus, 1 represents the first natural product that binds to and promotes the degradation of CD9. This study underscores the versatility of applying the PAL strategy for mechanistic studies and establishes 1 as a novel molecular platform for targeting CD9-mediated cellular pathways.